ClinicalTrials.gg
RecruitingNCT07533955Updated Oct 23, 2026

A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis

A Phase 1 interventional study of JADE201 and Placebo in Rhematoid Arthritis, sponsored by Jade Biosciences, Inc.. Recruiting at 8 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Jade Biosciences, Inc. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Oct 23, 2026First sites in 4 new countries5 sites addedGo to Updates ↓
Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a Phase 1, first in human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of JADE201 compared to placebo in participants with Rheumatoid Arthritis

Read the detailed description

This is a multisite, Phase 1, double-blind, placebo-controlled, randomized, first-in-human (FIH), single ascending dose study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of JADE201 in participants with Rheumatoid Arthritis. Approximately 36 evaluable participants (6 in each cohort) will be enrolled. JADE201 will be administered by a subcutaneous injection. The results of this study will form the foundation for subsequent clinical development of JADE201 in autoimmune indications.

02

Conditions studied

  • Rhematoid Arthritis
03

In context

Lead sponsor

Jade Biosciences, Inc. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants 18-70 years of age, inclusive.
  2. A body weight between 50-100 kg and a (BMI) between 18-32 kg/m2 (all inclusive) at screening.
  3. Confirmed diagnosis of RA according to 2010 ACR/EULAR criteria
  4. Willing and able to comply with the inpatient stay at the site, scheduled visits, treatment plans, laboratory tests, and other study procedures specified in the protocol.
  5. Willing and able to comply with and lifestyle requirements specified in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. With the exception of RA, known history of disease
  2. Diagnosis or symptoms suggestive of any systemic or inflammatory condition other than RA
  3. positive serology for Hep A, Hep B, or Hep C virus
  4. Positive, indeterminate, or invalid test of TB
  5. Current tobacco users who smoke >5 cigarettes per day or equivalent
  6. Nursing, lactating or pregnant, or who have plans to become pregnant during the study
  7. Treatment with an drug within 30 days or 5 half lives prior to study drug administration
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    JADE201

    Subcutaneous (SC) injection of JADE201

    Drug: JADE201

  • Experimental
    Placebo

    Subcutaneous (SC) injection of Placebo

    Drug: Placebo

Interventions

  • DrugJADE201

    JADE201 is supplied as sterile solution to be administered by SC injection.

  • DrugPlacebo

    Placebo solution to be administered at a matching volume by SC injection.

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of Single Ascending Doses of JADE201 in participants with Rheumatoid Arthritis

    Incidence of treatment-emergent adverse events

    Time frame: Day 1 through 36 weeks

Secondary outcomes

  1. Cmax

    Maximum observed serum concentration

    Time frame: Day 1 through Weeek 36

  2. Tmax

    Time to reach Cmax

    Time frame: Day 1 through Week 36

  3. AUClast

    The area under the concentration-time curve from time zero to the time of the last observed quantifiable (non-zero) concentration

    Time frame: Day 1 through Week 36

  4. T1/2

    Apparent first-order terminal elimination half-life

    Time frame: Day 1 through Week 36

07

Study locations

8 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Sites
5 sites added — first sites in Bulgaria, Georgia, Germany and Romania
Show 5 added (2 Romania, 1 Bulgaria, 1 Georgia, 1 Germany)
  • Jade Clinical Site · Sofia, Bulgaria
  • Jade Clinical Site · Tbilisi, Georgia
  • Jade Clinical Site · Berlin, Germany
  • Jade Clinical Site · Bucharest, Romania
  • Jade Clinical Site · Cluj-Napoca, Romania
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    5 sites added — first sites in Bulgaria, Georgia, Germany and Romania
    Show 5 added (2 Romania, 1 Bulgaria, 1 Georgia, 1 Germany)
    • Jade Clinical Site · Sofia, Bulgaria
    • Jade Clinical Site · Tbilisi, Georgia
    • Jade Clinical Site · Berlin, Germany
    • Jade Clinical Site · Bucharest, Romania
    • Jade Clinical Site · Cluj-Napoca, Romania
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07533955
Lead sponsor
Jade Biosciences, Inc.
Responsible party
Sponsor
First posted
Apr 16, 2026
Start date
May 19, 2026
Primary completion
Oct 2027 (estimated)
Completion
Oct 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Jade201 Study Contact
Contact
JADE201clinicaltrials@jadebiosciences.com
781-201-4781

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion